- Home
- FENC vs BNTC Comparison
FENC vs BNTC Comparison
Compare FENC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | BNTC |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | 35 | 24 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 396.3M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FENC | BNTC |
|---|---|---|
| Price | $10.88 | $10.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $14.50 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 239.3K | 99.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $176.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $9.85 |
| 52 Week High | $13.25 | $16.76 |
Technical Indicators
Market Signals| Indicator | FENC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 35.19 |
| Support Level | $10.88 | $10.04 |
| Resistance Level | $11.28 | $14.14 |
| Average True Range (ATR) | 0.50 | 0.65 |
| MACD | -0.18 | -0.17 |
| Stochastic Oscillator | 28.44 | 8.56 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.